CD274 and neoplasm: Upon employing PLX3397 to deplete macrophages, the non-phagocytized PD-L1 antibodies dissociated from TEVs favoring the binding between anti-PD-L1 mAbs and PD-L1 on tumor cells, thereby abolishing anti-PD-L1 therapeutic resistance.